These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22395574)

  • 1. Structural and pharmacological profile of generic enoxaparins used in Brazil.
    Lima MA; de Farias EH; Gray A; Sadeghi N; Gesteira TF; Cavalheiro RP; Hoppensteadt D; Fareed J; Sassaki GL; Nader HB
    Clin Appl Thromb Hemost; 2012 Jul; 18(4):379-86. PubMed ID: 22395574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Immunostimulatory Potential of Branded and US-Generic Enoxaparins in an In Vitro Human Immune System Model.
    Luna E; Agrawal P; Mehta R; Vernhes C; Viskov C; Amiral J; Warren WL; Drake DR
    Clin Appl Thromb Hemost; 2015 Apr; 21(3):211-22. PubMed ID: 25525049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure and haemostatic effects of generic versions of enoxaparin available for clinical use in Brazil: similarity to the original drug.
    Glauser BF; Vairo BC; Oliveira SN; Cinelli LP; Pereira MS; Mourão PA
    Thromb Haemost; 2012 Feb; 107(2):302-14. PubMed ID: 22234635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thromboelastographic evaluation of blood coagulation in the presence of branded and generic enoxaparins.
    Walenga JM; Jeske WP; Escalante V; Hoppensteadt D; Fareed J; Bakhos M
    Int Angiol; 2012 Dec; 31(6):517-25. PubMed ID: 23222929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
    Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiation of generic enoxaparins marketed in the United States by employing NMR and multivariate analysis.
    Guerrini M; Rudd TR; Mauri L; Macchi E; Fareed J; Yates EA; Naggi A; Torri G
    Anal Chem; 2015 Aug; 87(16):8275-83. PubMed ID: 26189325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generic versus branded enoxaparin in the prevention of venous thromboembolism following major abdominal surgery: report of an exploratory clinical trial.
    Gomes M; Ramacciotti E; Henriques AC; Araujo GR; Szultan LA; Miranda F; Thethi I
    Clin Appl Thromb Hemost; 2011; 17(6):633-9. PubMed ID: 21949036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analytical and statistical comparability of generic enoxaparins from the US market with the originator product.
    Mourier PA; Agut C; Souaifi-Amara H; Herman F; Viskov C
    J Pharm Biomed Anal; 2015 Nov; 115():431-42. PubMed ID: 26280926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
    Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
    Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural and functional analyses of biosimilar enoxaparins available in Brazil.
    Oliveira SN; Santos GR; Glauser BF; Capillé NV; Queiroz IN; Pereira MS; Pomin VH; Mourão PA
    Thromb Haemost; 2015 Jan; 113(1):53-65. PubMed ID: 25252953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan.
    Tsai YS; Lan SK; Ou JH; Tzai TS
    Clin Ther; 2007 Apr; 29(4):670-82. PubMed ID: 17617290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When is a "generic" medication not really a generic?
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2010 Feb; 48(2):13-6. PubMed ID: 20166651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of the switch from a branded to a generic warfarin sodium product: an observer-blinded, randomized, crossover study.
    Lee HL; Kan CD; Yang YJ
    Clin Ther; 2005 Mar; 27(3):309-19. PubMed ID: 15878384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative studies on branded enoxaparin and a US generic version of enoxaparin.
    Walenga JM; Jeske WP; Hoppensteadt D; Cunanan J; Khan H; Escalante V; Fareed J; Bakhos M
    Clin Appl Thromb Hemost; 2013 Jun; 19(3):261-7. PubMed ID: 23091283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on Brazilian biosimilar enoxaparins.
    Vilanova E; Glauser BF; Oliveira SM; Tovar AM; Mourão PA
    Expert Rev Hematol; 2016 Nov; 9(11):1015-1021. PubMed ID: 27680213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro disintegration studies of weekly generic and branded risedronate sodium formulations available in Canada.
    Walker AD; Adachi JD
    Curr Med Res Opin; 2011 Sep; 27(9):1749-54. PubMed ID: 21781014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study.
    Desai RJ; Sarpatwari A; Dejene S; Khan NF; Lii J; Rogers JR; Dutcher SK; Raofi S; Bohn J; Connolly J; Fischer MA; Kesselheim AS; Gagne JJ
    BMJ; 2018 Apr; 361():k1180. PubMed ID: 29615391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use and cost of branded and generic drugs in patients with coronary heart disease--results from a prospective survey of 1008 patients in two London hospitals.
    Corp EV; Antoniou S; Wright PG; Khachi H; Vercaeren S; Wald DS
    QJM; 2009 Dec; 102(12):843-9. PubMed ID: 19828644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview on guidelines and recommendations for generic low-molecular-weight heparins.
    Harenberg J
    Thromb Res; 2011 Feb; 127 Suppl 3():S100-4. PubMed ID: 21262425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.